版本:
中国

BRIEF-First dedicated outcome trials of empagliflozin in chronic heart failure initiated

March 17 Eli Lilly And Co

* First dedicated outcome trials of Empagliflozin in chronic heart failure initiated

* Emperor HF comprises two phase III outcome studies that will investigate empagliflozin for treatment of adults with chronic heart failure

* Trials will involve not only adults with type 2 diabetes who have heart failure, but also heart failure patients who do not have diabetes

* Emperor HF's two trials will involve approximately 7,000 patients in total and are anticipated to complete in 2020 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐